]>
IRCT20230523058271N1 IRCT 2023-10-08 Yazd University of Medical Sciences Evaluation of the efficacy of Pentoxiphyllin in hospitalized diabetic patients with covid19 Evaluation of the efficacy of Pentoxiphyllin in hospitalized diabetic patients with covid19 2023-01-12 anticipated 50 Complete https://irct.ir/trial/70311 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who meet the inclusion criteria are divided into two groups by a simple randomization method and based on the table of random numbers prepared by the statistics consultant whom out of the study, and the grouping of each person is in a sealed envelope at the disposal of the relevant doctor and the nursing team. will be placed, Blinding description: In this double-blind study, the researcher and the statistical analyst will not know about the grouping. In this way, only the doctor who prescribed the patient's orders, the nursing team and the patient knew about the medicine received, and the researcher who was responsible for collecting the information and results of the patients would not know about the grouping, and the statistical researcher would also know that each of It will not be known what drugs the groups received. 3 covid 19. Intervention 1: Intervention group: They are treated with pentoxifylline 400 mg three times a day along with intravenous dexamethasone 4 mg every 12 hours. Intervention 2: Control group: They are treated with intravenous dexamethasone 4 mg every 12 hours. Yes - There is a plan to make this available What will be shared: Only a part of the data, such as the information related to the main outcome or the like, can be shared. When: One year after the time of publication To whom: The data will be available only to researchers working in academic and scientific institutions Conditions: The data will be available only to researchers working in academic and scientific institutions Where to obtain: The data will only be available to researchers working in academic and scientific institutions through the following email address. How to obtain: Only the data related to the main results of the study can be presented to the mentioned people after mentioning the valid reason. Comments:
public Zahra Falahati marvast
Faculty of Pharmacy, Shohday gomnam Boulevard, Alam Square, Yazd, Iran
yazd Iran (Islamic Republic of) 8916978477 +98 35 3837 4597 zs.falahati1988@gmail.com Yazd University of Medical Sciences scientific Zahra Falahati marvast
Faculty of Pharmacy, Shohday gomnam Boulevard, Alam Square, Yazd, Iran
yazd Iran (Islamic Republic of) 8916978477 +98 35 3837 4596 zs.falahati1988@gmail.com Yazd University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Diagnosis of covid in the last 24 to 48 hours Candidate for hospitalization (o2sat<93% or RR>24 or Pao2/Fio2<300) Covid-19 patients who are candidates for hospitalization with indications for hospitalization according to the country's guidelines, who had pulmonary infiltration in CT scan Outpatients with pulmonary infiltration on CT scan Age 18 to 70 years 18 years 70 years Both Patients who were treated with Coltera (lupinavir/ritonavir). Patients with shock or hemodynamic instability Drug intolerance Patients with a history of Crohn's or ulcerative colitis, diarrhea or chronic malabsorption Neuromuscular diseases GFR less than 30 ml/min History of cirrhosis, hepatitis and severe liver diseases Patients receiving chemotherapy for cancer Pregnancy and breastfeeding Post-COVID U09 Treatment - Drugs Treatment - Drugs Intervention group: They are treated with pentoxifylline 400 mg three times a day along with intravenous dexamethasone 4 mg every 12 hours. Control group: They are treated with intravenous dexamethasone 4 mg every 12 hours. Recovery. Timepoint: It is evaluated during the first 72 hours after hospitalization and the start of the intervention. Method of measurement: It is evaluated in the form of arterial blood oxygen level of at least 93%, cessation of fever for 72 hours and improvement of the general condition through a questionnaire. IL-6. Timepoint: At the start of treatment and after one week from the start of treatment. Method of measurement: kit. CRP. Timepoint: At the start of treatment and after one week from the start of treatment. Method of measurement: kit. ESR. Timepoint: At the start of treatment and after one week from the start of treatment. Method of measurement: KIT. Ferritin. Timepoint: At the start of treatment and after one week from the start of treatment. Method of measurement: kit. Involvement in HRCT. Timepoint: At the start of treatment and after one week from the start of treatment. Method of measurement: Using CT SCAN observation and evaluation by a lung specialist. Hospitalization in ICU. Timepoint: During the course of treatment. Method of measurement: CHECKLIST. Death. Timepoint: During the course of treatment. Method of measurement: CHECKLIST. Research Vice President of Yazd University of Medical Sciences Approved 2023-01-11 Shahid Sadoughi University of Medical Sciences, Yazd Shahid Sadoughi University of Medical Sciences, Shohday gomnam Boulevard, Alam Square, Yazd, Iran yazd Yazd Iran (Islamic Republic of)